Table 1. Selected ongoing precompetitive neuroscience industry collaborations.

Initiative

Research goals

Industry partners

Nonindustry partners

Funding or organizing body

 Committed fundingA

 Launched

CommonMind Consortium

Generate and analyze large-scale genomic data from patients with neuropsychiatric diseases

2

3

Sage Bionetworks

Undisclosed

2012

EU-AIMS: European Autism Interventions-A Multicenter Study for Developing New Medications

Develop autism research tools and diagnostics, and help select clinical endpoints for future trials

9

16

Innovative Medicines Initiative (IMI)

€35.9 million ($48.1 million)

2012

Parkinson's Progression Markers Initiative

A multisite observational clinical trial to determine the characteristics of Parkinson's disease (PD) progression

11

Not
applicable

The Michael J. Fox Foundation for Parkinson's Research

$45 million

2010

PharmaCog: Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development

Develop and validate new tools to test Alzheimer's disease (AD) drugs

16

13

IMI

€27.7 million ($37.1 million)

2010

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia

Develop new animal models and clinical trial tools for schizophrenia and depression

13

7

IMI

€24 million ($34.6 million)

2009

EUROPAIN: Understanding Chronic Pain and Improving its Treatment

Identify mechanisms that contribute to pain, using new experimental models, human volunteers and clinical data of pain patients

8

12

IMI

€18.2 million ($26.2 million)

2009

Coalition Against Major Diseases

Advance innovative tools and technologies through a regulatory path that accelerate the development of medical products for neurodegenerative diseases

16

Undisclosed

Critical Path Institute

Undisclosed

2008

Alzheimer's Disease Neuroimaging Initiative

A multisite observational clinical trial to determine the characteristics of AD progression

25

3

Foundation for the National Institutes of Health and the National Institute on Aging

$130 million

2004

AInnovative Medicines Initiative projects include value of in-kind contributions.